Scanax 500

Scanax 500 contains ciprofloxacin, a fluoroquinolone antibacterial with a wider spectrum of activity than nalidixic acid, and more favorable pharmacokinetics allowing its use in systemic infections.

Pack size Box of 50 tablets. Bottle of 100 tablets, 500 tablets.
Shelf-life 48 months
Composition Ciprofloxacin
Dosage forms and strengths Film coated tablet: 500 mg
Product code :



  • Upper urinary tract infection.
  • Uncomplicated gonorrhea.
  • Chronic prostatitis.
  • Infections in skin, soft tissues and bone.
  • Severe bacterial enteritis.
  • Prophylaxis against meningococcal diseases.
  • Prophylaxis against Gram (-) infections in immune suppressed patients.
  • Severe nosocomial infections (septicemia and treatment of infections in immune suppressed patients).
  • Uncomplicated urinary tract infections.
  • Acute bacterial exacerbations of chronic bronchitis.
  • Acute bacterial sinusitis.


The treatment should be continued for at least 48 hours, after all disease symptoms have been disappeared. Period of treatment is usually 1 – 2 weeks. In cases of bone or joint infection, the ciprofloxacin treatment must be continued for 4 – 6 weeks or more long. Infectious diarrhea can be treated within 3 – 7 days or in a shorter time.

  1. Upper urinary tract infection: 500 mg twice a day.
  2. Uncomplicated gonorrhea: 500 mg, as a single dose.
  3. Chronic prostatitis: 500 mg twice a day.
  4. Infections in skin, soft tissues and bone: 500 mg twice a day.
  5. Severe bacterial enteritis: Treatment: 500 mg twice a day; prophylaxis: 500 mg once a day.
  6. Prophylaxis against meningococcal diseases: Adults and children > 20 kg: 500 mg, single dose.
  7. Prophylaxis against Gram (-) infections in immune suppressed patients: 500 mg twice a day.
  8. Severe nosocomial infections (septicemia and treatment of infections in immune suppressed patients): 500 mg twice a day.
  9. Uncomplicated urinary tract infections: 250 mg twice a day, for 3 days (use another dosage form).
  10. Acute bacterial exacerbations of chronic bronchitis: 500 mg twice a day, for 7 – 14 days.
  11. Acute bacterial sinusitis: 500 mg twice a day, for 10 days.

Doses should be reduced in patients with severe renal impairment.


Scanax 500 is administered orally, should be given 2 hours after a meal. The patient should drink fluids liberally and not take antacids within 2 hours after digestion.

  • In patients hypersensitive to ciprofloxacin or other quinolones or any of the excipients.
  • Concomitant administration of ciprofloxacin and tizanidine.
  • Take into account when prescribing ciprofloxacin to children and growing adolescents.
  • Disabling and potentially irreversible serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects.
  • Common: Nausea, vomiting, diarrhoea, abdominal pain; transient increases in serum transaminases.
  • Uncommon: Headache, drug induced fever; tachycardia; agitation; joints pain and swelling.
  • Avoid the use of fluoroquinolones in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones. Discontinue this medicine immediately at the first signs or symptoms of any serious adverse reactions.
  • Treatment with ciprofloxacin must be halted immediately if:
    • There are first signs of hypersensitivity reactions.
    • Patients experience tendon pain, inflammation, or rupture.
  • Extreme caution should be exercised when use ciprofloxacin for:
    • Patients with myasthenia.
    • Patients with renal impairment.
    • Patients with G6DP deficiency.
    • Patients with epilepsy or a history of CNS disorders.
  • Exposure to strong sunlight or sunlamp should be avoided during treatment with ciprofloxacin.
  • Ciprofloxacin and other fluoroquinolones should be avoided in Methicillin-resistant Staphylococcus aureus (MRSA) infections.
  • Ciprofloxacin may cause negative of the bacteriological tests of Mycobacterium tuberculosis.
  • Ciprofloxacin is only used for pregnancy with severe infection that was not manageable with therapeutic dosages of other antibiotic agents, use of fluoroquinolone is an obligatory therapy. If continued use is considered obligatory, mother should discontinue nursing.
  • Patients should be aware of how they react to drug before driving or operating machinery. Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient’s ability to concentrate and react.